Compare Cintas Corporation (CTAS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Cintas Corporation trades at $200.75 (market cap $78.78B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Cintas Corporation pays a 1.05% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CTAS | VRTX | |
|---|---|---|
Market Cap | $78.78B | $128.16B |
Volume | 1,620,783 | 806,603 |
Sector | Industrials | Health |
52-Week High | $216.53 | $557.96 |
52-Week Low | $163.55 | $407.37 |
Typical Hold Time | 124 Days | 120 Days |
Enterprise Value | $81.25B | $122.29B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal and strong fundamental performance. Recent Q1 2027 earnings beat expectations with revenue of $3.01 billion and EPS of $1.39, driven by organic growth and margin expansion. The company raised fiscal 2027 guidance, reflecting confidence in continued momentum. Valuation multiples remain elevated with a P/E of 38.89, supported by robust profitability metrics including a 17.82% net income margin and 42.08% ROE.
The outlook for CTAS is positive, with earnings growth and raised guidance serving as key catalysts for potential upside toward the consensus price target of $234.60. Risks include high valuation sensitivity to growth sustainability and competitive pressures in the uniform rental sector. Analyst sentiment is moderately bullish, with 40% buy ratings, but investors should monitor execution against elevated expectations.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
